Abstract: Huprine X (HX) is a synthetic anticholinesterasic compound that exerts a potent inhibitory action on acetylcholinesterase (AChE) activity, an agonist effect on cholinergic receptors, neuroprotective activity in different neurotoxicity models in vivo and in vitro and cognition enhancing effects in non-transgenic (C57BL/6) and transgenic (3xTg-AD, APPswe) mice. In this study, we assessed the ability of HX (0.8 mg/kg, 21 days) to prevent the damage induced by kainic acid (KA; 28 mg/kg) regarding apoptosis, glia reactivity and neurogenesis in mouse brain. KA administration significantly modified the levels of pAkt1, Bcl2, pGSK3b, p25/p35, increased the glial cell markers and reduced the neurogenesis process. We also observed that pre-treatment with HX significantly reduced the p25/p35 ratio and increased synaptophysin levels, which suggests a protective effect against apoptosis and an improvement of neuroplasticity. The increase in GFAP (88%) and Iba-1 (72%) induced by KA was totally prevented by HX pre-treatment, underlying a relevant anti-inflammatory action of the anticholinesterasic drug. Our findings highlight the potential of HX, in particular, and of AChEIs, in general, to treat a number of diseases that course with both cognitive deficits and chronic inflammatory processes.
Neurodegenerative diseases such as Alzheimer's, Parkinson's and recurrent seizures diseases share at least three common pathophysiological processes, namely apoptosis, neuroinflammation and oxidative stress. Acetylcholinesterase inhibitors, (AChEIs: tacrine, donepezil, rivastigmine and galantamine) are the drugs currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease [1] [2] [3] , in addition to memantine, a glutamate-modulating drug. However, the therapeutic benefit of AChEIs is not entirely explained by the increased activity of the cholinergic system. Indeed, it is known that AChEIs have multiple effects on the central nervous system, some of which could be regarded as broadly neuroprotective [2, 4, 5] . Consequently, although they do not halt the underlying degenerative process, AChEIs can slow disease progression through different mechanisms.
Huprines, a group of AChEIs, which are the result of the molecular hybridization of tacrine and huperzine A, display a potent and selective inhibitory action on AChE in both in vivo and ex vivo studies [6] . Moreover, they have demonstrated other beneficial actions beyond their ability to inhibit AChE. Previously, we have demonstrated the agonist activity of huprines on both muscarinic and nicotinic acetylcholine receptors in different experimental approaches. [7, 8] . We have also shown that due to this agonist effect, huprines protect NGFdifferentiated PC12 cells against the injury induced by hydrogen peroxide [9] . Different data point out that nAChRs are involved in the activation of survival signal transduction and other anti-apoptotic mechanisms that may lead to neuroprotection [10] . Accordingly, pre-clinical studies confirm that alpha-7 nAChRs expressed in macrophages and immune cells also mediate anti-inflammatory effects by modulating the immune system [11] .
Interestingly, some in vivo studies show some neuroprotective effects of HX. Thus, 3xTg-AD mice, treated with the drug, show improved cognition, likely as a result of the regulation of some neurochemical processes, such as those mediated by a-secretases and glycogen synthase kinase 3-b (GSK3b) [12] . Moreover, an increase in the synaptophysin levels and a reduction in Ab1-40 in the same mouse model have also been described [13] . It is known that AChE promotes the amyloidogenic process through the peripheral binding site of the enzyme [14] , and this process can be significantly blocked by huprines [15] .
The aforementioned biological activities of HX prompted us to further profiling its neuroprotective effects against another neurotoxic insult such as kainic acid (KA). It is known that KA mainly causes neuronal degeneration in CA3/CA1 regions of the hippocampus leading to impairment in learning and memory through over stimulation of AMPA/KA glutamate receptors [16] . Thus, KA induces cell death as a consequence of the alteration of a wide range of signal transduction pathways, inflammation and oxidative pathways, among other neurodegenerative processes [17, 18] . In particular, we have assessed the ability of HX, to prevent the alterations caused by KA on Akt1, Bcl2, GSK3b, caspases, p25/p35 and synaptophysin involved in the pro-/anti-apoptotic pathway and neuroplasticity, in addition to GFAP, Iba-1 as glial markers and DCX to analyse changes in the neurogenesis process. Also, the expression of AChE variants (-R,-S) after chronic treatment with the inhibitor has been determined, as the expression of both enzyme variants is involved in neurotoxicity/neuroprotection mechanisms [19, 20] .
Materials and Methods
Animals. Eight-week-old C57BL/6 male mice (n = 30) were maintained in the facilities of the Universitat Aut onoma de Barcelona. Five animals were housed per cage in standard plastic type Macrolon cages (35 9 35 9 19 cm, with 2 L of wood cuttings as bedding) until the time of the experiment. They were maintained at room temperature (22 AE 2°C) with 60 AE 10% relative humidity and a 12-hr light/dark (LD) schedule with lights on at 08:00 a.m. The animals had laboratory chow and tap water ad libitum until the moment of the test. All of the research was conducted in compliance with the Spanish legislation on 'Protection of Animals Used for Experimental and Other Scientific Purposes' and in accordance with EU Directive 08-88 on this subject. Moreover, the study complies with the ARRIVE guidelines developed by the NC3Rs [21] . All efforts have been made to reduce the number of animals used and to minimize animal suffering.
Drug treatment and experimental design. (AE)-Huprine X (HX) was synthesized and obtained from the Laboratori de Qu ımica Farmac eutica (Facultat de Farm acia I Ciencies de la Alimentaci o, Universitat de Barcelona) [22] . The drug was dissolved in a vehicle of 0.9% saline solution for chronic intraperitoneal injection (ip; 0.80 mg/ kg) in a volume of 10 mL/kg to a group of 10 animals, at 3:00 p.m. daily for 21 days (HX group). The rest of the animals (n = 20) received saline solution during the same period. One day after the last HX dose, both the HX and one of the saline groups received KA (ip; 28 mg/kg dissolved in saline; Ocean Produce International, Canada). The rest of the saline-treated mice were used as a control group (n = 10) and received ip saline solution.
To verify neurotoxic induction by KA, all groups of mice (saline + saline; saline + KA and HX + KA) were observed every 30 min. for 4 hr after KA and HX-KA injection. All KA-treated animals displayed general limbic seizure activity within 90 min. of KA administration. The behavioural scores were as follows: 0, no response; 1, immobility; 2, rigid posture; 3, scratching/circling/head bobbing; 4, forelimb clonus/rearing/falling; 5, repetitive pattern of 4; and 6, severe tonic-clonic seizures [23] . Each mouse showed several of these behavioural parameters along the observation period. The control group (saline + saline) did not show any response. The mice were killed 48 hr after KA administration as it has been shown that this waiting time is suitable for detecting changes in the different proteins and related neurodegeneration processes [24] . Immediately thereafter, their brains were removed from the skull and both hippocampi and cortex were quickly excised. Finally, the tissues were frozen at À80°C until subsequent analysis.
Western blotting. For western blotting (WB), three to five hippocampi or cortex samples from each treatment group were individually homogenized using a Polytron apparatus on ice, freshly prepared buffer 1:20 dilution [1 M Tris-HCI (pH 7.5), 0.5 M EDTA (pH 8); 1% Triton X-100, protease inhibitor cocktail and phosphatase inhibitor cocktail]. Homogenates were centrifuged at 12,000 9 g for 10 min. at 4°C, and the supernatant (soluble proteins) was frozen at À80°C.
Proteins determined by the Bradford assay (30 lg/lane) were separated onto 7.5% sodium dodecyl sulphate polyacrylamide gel and transferred to nitrocellulose membranes [Trans-Blot Turbo-Transfer System (BioRad, California, USA); 25 V, 1A, 30 min.]. The membranes were blocked with 5% (w/v) non-fat dry milk in T-BST (tris-buffered saline containing Tween-20; 2.5 mMTris-HCl pH 7.5, 0.09% NaCl, 0.2% Tween-20) for 45 min. at 25°C and rinsed three times for 5 min. in T-BST. They were then incubated with the appropriate primary antibody (table 1) , overnight at 4°C, rinsed twice with T-BST and incubated with a secondary antibody (horseradish peroxidase) for 1 hr at 25°C. b-Actin was assayed simultaneously using the b-Actin monoclonal antibody as the primary antibody.
The immunoblots were developed with WB detection ECL reagents. Quantification of results was carried out using the GeneSnap programme, and the optical density of each sample was corrected using the optical density of the corresponding b-Actin band.
Samples from treated mice (saline + KA and HX + KA groups) were evaluated as a percentage of the control group (saline + saline) for each experiment (WB membrane); consequently, values are mean of the percentages compared to the control group.
Immunohistochemistry. Five mouse half-brains were fixed in 4% paraformaldehyde in PBS (phosphate-buffered saline pH 7.4; NaCl 0.137 M; KCl 0.0027 M; Na 2 HPO 4 .2H 2 O 0.02 M; K 2 HPO 4 0.1 M) and maintained at 4°C for 24 hr. Afterwards, brains were rinsed three times in 30% sucrose solution in PBS and frozen by isopentane. Sagittal sections of 20 lm were maintained in freeze solution (PBS 30%; ethylene glycol 40%; glycerol 30%) at À20°C until the subsequent analysis. Immunohistochemistry was performed freefloating, using the antibodies included in table 2.
Sagittal sections (20 lm) were washed three times in PBS for 20 min. and once in T-PBS (phosphate-buffered saline containing 0.3% triton-X100) for 7 min. They were pre-incubated in T-PBS with 0.5% bovine serum albumin (BSA) to reduce non-specific binding for 45 min. at 25°C. Sections were incubated with the primary antibodies in T-PBS with 0.1% BSA overnight at 4°C. On the following day, they were rinsed three times in T-PBS for 10 min. and incubated with the secondary antibodies in T-PBS (0.1% BSA) for 1 hr at 25°C. Finally, sections were washed three times in PBS for 10 min. each time. Hoechst reagent was used as a nuclear marker, which was added directly to the wells 30 min. before the end of the secondary antibody incubation, at a final concentration of 1 lg/mL.
Brain sections were mounted on slides (six cuts per slide). Dentate gyrus (DG) labelling was observed under fluorescent light at optimal sensitivity using an appropriate filter system. The 209 images were analysed by ImageJ 1.49 free software. Non-specific binding was determined in samples in which the primary antibody was not present. Then, these samples were used as the background for the evaluation of the three experimental groups. Samples from treated mice (saline + KA and HX + KA groups) were evaluated as a percentage of arbitrary fluorescence units of the control group in each experiment (n = 3).
Caspase activity. Cortical brain tissues were homogenized, and protein concentrations were quantified by the Bradford method [25] .
Caspase-3/7, caspase-8 and caspase-9 activities were measured using the corresponding Caspase-Glo Assay kits (Promega, Madison, WI, USA). Briefly, 20 lL (5 lg/lL) of protein extracts of each tissue was added to an equal volume of Caspase-Glo reagents (20 lL) and caspase activity was measured at 40 min. after starting the reaction, and also every 20 min. during 2 hr, the maximum luminescent signal being the chosen one, using a Victor 3 Multilabel Counter (Perkin Elmer, Wellesley, MA, USA). Luminescence units were used to evaluate the effects of drug treatments on caspase activity.
RT-PCR. A brain regional study demonstrated that the induction of AChE-R transcripts by AChE inhibitors is higher in the frontal cortex than in other brain areas in mice [26] . Consequently, the frontal cortex was used for AChE variants analysis. Total RNA was isolated from the frontal cortex using PureLink TM RNA Mini Kit (Life Technologies, Warrington, UK). Traces of DNA were removed by RNase-free DNase I treatment (Life Technologies). Ten microgram of pure RNA was subsequently used and subjected to real-time PCR (RT-PCR) to quantify expressions of AChE variants (-R,-S) (Life Technologies).
Forward and reverse primers of AChE-R and -S variants and b-Actin mRNA used for amplifying specific cDNAs [27] were obtained from Invitrogen (Life Technologies). For the amplification process, the RTBiorad CFX96 system was used. A MicroAmp Optical 96-well reaction plate with 25 lL of reaction volume was subjected to a first step of 5 min. at 50°C, and 40 cycles of 15 sec. at 95°C and 1 min. at 60°C. The final dissociating step was added to analyse the melting curves. The results, expressed in cycles (Ct), were normalized to the amount of control gene (b-Actin) and linearized using the formula 2
Àct according to the method described by Kenneth J. Livak et al., [28] . The mRNA expression levels were considered to be 100% for control mice.
Statistics. All neurochemical experiments were performed using three to five mice per treatment group, and three to four experiments were run at least in duplicate and expressed as means AE S.E.M. The Student's t-test for unpaired samples and one-way ANOVA followed by Dunnett's test were used, according to the experimental approach. Statistical significance was considered at p < 0.05.
Results
Effects of huprine X on seizures induced by acute treatment with kainic acid. Behavioural responses of mice to KA and HX-KA administration were assessed as described in Materials and Methods. Results depict the average score rating AE S.E.M. No significant differences regarding behavioural response were observed (table 3) .
Effects of huprine X pre-treatment on apoptosis (Akt1, Bcl2, GSK3b, caspases), and neuroplasticity (p25/p35, synaptophysin) changes induced by acute treatment of kainic acid. Akt-PI3K is an important pathway that leads to phosphorylation of a plethora of downstream cytoplasmic and nuclear targets, being crucial in the survival process. Thus, Akt modulates the activation of different factors involved in cell death: GSK3, caspases and BAD, among others [29] . We found a significant decrease in the levels of activated phosphorylated Akt1 (pAkt1) in both brain areas at 48 hr after KA administration when compared with control mice ( fig. 1 ; p < 0.05; n = 4). On the other hand, non-phosphorylated Akt1 levels increased significantly in the cortex but remained unchanged in the hippocampus ( fig. 1 ; p < 0.05; n = 4). When mice were previously treated with the anticholinesterase drug HX, it did not significantly modify the effects exerted by KA on pAkt1 in the hippocampus. However, in the cortex, HX pre-treatment prevented the KA-induced decrease in pAkt1 and the increase in Akt1 levels, respectively. The Bcl2 protein family governs mitochondrial membrane permeability and includes both pro-apoptotic and anti-apoptotic proteins. In this study, we focused our interest on the antiapoptotic protein Bcl2, which inhibits the intrinsic pathway of cell death. In this regard, a significant decrease in Bcl2 expression was observed after KA administration both in the hippocampus and cortex ( fig. 2 ; p < 0.001). Interestingly, HX pre-treatment completely prevented the KA-induced decrease of Bcl2 protein levels in the hippocampus, so that no significant differences between the HX-KA group and control group (serum) were found. In contrast, HX pre-treatment did not modify the effect of KA on this protein in the cortex.
GSK-3b, which is a downstream target of the PI3K/Akt pathway, plays an important role in neuronal cell death [30] by both enhancing the expression of pro-apoptotic proteins like cytosolic cytochrome c, cleaved caspase-3, and inhibiting the activity of anti-apoptotic proteins [31] . The best characterized mechanism of inactivation of GSK3b involves the phosphorylation of its N-terminus at Ser9. After KA administration, an increase was found in the phosphorylated form of the protein (pGSK3b) both in the hippocampus (46%, p < 0.05) and in the cortex (53%, p < 0.01) (fig. 3 ). The same figure shows that pre-treatment with HX did not significantly change the effect induced by KA in either of the areas.
Caspases are a family of proteases that are activated under apoptotic stimuli, promoting cell death. The role of caspase-3 is to activate an endonuclease involved in DNA degradation. In this study, we found that KA did not induce any modification in the caspase-3/7 activity in the cortex (control = 8952 AE 1507; KA = 9764 AE 2195; HX + KA = 10,449 AE 1070; luminescence units).
Cyclin-dependent kinase-5 (CDK5) has been involved in the modulation of synaptic plasticity, among other processes. The interaction of CDK5 with p35 or p39 leads to the activation and recruitment of CDK5 in cellular membranes both in the cell soma and within dendrites, while the interaction with p25 plays an important role in the pathogenesis of neurodegenerative diseases [32] . In this study, the p25/p35 ratio as an indicative parameter of CDK5 inactivation/activation degree has been analysed. As can be observed in fig. 4 , KA administration significantly increased the p25/p35 ratio (p < 0.05) in the hippocampus. The preventive treatment with HX not only abolished the effect of KA, but it also significantly decreased the p25/p35 ratio compared to the control group. No modifications were detected in the p25/p35 ratio after KA administration in the cortex. Synaptophysins, a type of 38-kDa calcium-binding glycoproteins found in presynaptic vesicles of presynapsis, have been widely used as a marker of synaptogenesis. The densitometric analysis of synaptophysin showed only a slight but non-significant decrease in the protein content in the KA-treated group in both hippocampus and cortex ( fig. 5 ). Interestingly, a significant increase in synaptophysin content over both KA (p < 0.01) and control groups (p < 0.01) was found in both the hippocampus and cortex of the HX-KA-treated mice.
Effects of huprine X on neuroinflammation (GFAP, Iba-1) and neurogenesis (DCX) in the brain of mice subjected to acute treatment with kainic acid. In the adult brain, glial fibrillary acidic protein (GFAP) is widely known as a marker of mature astrocytes activation. GFAP is a filament protein, whose expression increases with age in animal models and under pathological conditions in which oxidative stress may play a role. KA administration Fig. 1 . Effects of KA and HX pre-treatment on pAKt (Ser473) and Akt in the hippocampus and cortex of C57BL/6 male mice. Photodensitometric quantification of WB experiments was used to evaluate changes in pAkt (Ser473) and Akt expression. Experiments (n = 4) were developed at least in duplicate on three to four animals and expressed as means AE S.E.M. The statistical analysis used was one-way ANOVA followed by Dunnett's test *p < 0.05 versus control; a p < 0.05 versus KA.
induced a significant increase (88%; p < 0.001) in the fluorescence detected by the immunofluorescence technique in the DG ( fig. 6 ), which was totally prevented upon pre-treatment with HX (p < 0.001).
Ionized calcium-binding adaptor molecule 1 (Iba-1) has been widely used to study microglia as its expression is specific and it is up-regulated during inflammatory processes. In response to acute administration of KA, an increase of 72% of Iba-1 (p < 0.001) was found at the DG in the hippocampus. Also in this case, pre-treatment with HX (p < 0.001) completely prevented the KA effect on activated microglia ( fig. 6 ). Doublecortin (DCX) is a protein expressed during development of immature neurons that is used as marker of neurogenesis. Figure 6 shows the results obtained in immunofluorescence analysis. We observed that in the presence of KA, the levels of DCX significantly diminished (p < 0.01), but pre-treatment with HX was not able to protect mice against the KA effect.
Effect of kainic acid on AChE isoforms (-R, -S): huprine X modulation.
It is known that the expression of alternative splicing patterns of AChE genes can be modified by stress insults (Zimmerman et al. [19] ). Alternative splicing at the 3 c-terminus of AChE pre-mRNA yields three variants: the primary, 'synaptic' AChE-S (otherwise known as 'tailed', AChE-T), the stressinduced, soluble (readthrough) AChE-R variant and the erythrocytic AChE-E.
The RT-PCR analysis of the two AChE variants (-R, -S) is shown in fig. 7 . As it can be observed ( fig. 7A ), mRNA-S levels were higher than those of mRNA-R in the frontal cortex of control animals, even though differences were not significant. After KA administration, mRNA-R levels increased significantly over the control group, while mRNA-S levels were similar in all experimental conditions ( fig. 7B) . Although pretreatment with HX led to a slight decrease in the -R isoform relative to the KA group, this was not significant.
Discussion
Previous studies have demonstrated that HX improves learning and memory processes, restores some anti-apoptotic proteins in non-transgenic and in 3xTg-AD mice and also shows neuroprotective activity in cell culture [9, 12, 13, 33] . The findings obtained herein show that pre-treatment with HX protects mice against changes on pro-/anti-apoptotic pathways and on the neuroinflammation process induced by KA without exacerbating seizures induced by neurotoxin.
An increase in both glutamatergic and cholinergic neurotransmission in the brain can account for the development of seizures [34] . In the present study, the score rating of seizures induced by KA was not modified in those mice previously treated with HX, a cholinomimetic drug. This is an important finding, especially because patients with Alzheimer's disease exhibit a higher risk of developing epileptic seizures as compared with non-demented patients of similar age [35] . However, it has been reported that treatment with acetylcholinesterase inhibitors rivastigmine and donepezil induces seizures as an adverse effect in 6.41 and 8.74% of patients, respectively [36] .
It is known that after brain damage several neuroplastic changes take place. In agreement with previously reported results [37] , in the present study we found significantly decreased levels of pAkt1 and Bcl2 in both the hippocampus and cortex after KA administration. Pre-treatment with HX did not significantly modify the decrease of pAkt1 and Bcl2 observed in KA-treated mice. Because Akt1 has been related to epileptic seizures, the fact that pre-treatment with HX did not modify seizures induced by KA would be in correlation with the lack of significant effects of HX on pAkt1 and Bcl2 levels.
It should be noted that, in the present experimental approach, KA was administered 24 hr after the last injection of HX, and mice were killed 2 days after the KA injection. In consequence, proteins were analysed 3 days after the last dose of HX when the presence of the drug in the animals cannot be detected (data not shown). Therefore, we must emphasize that we have evaluated the potential protective effects of HX, beyond symptomatic actions arising from AChE inhibition or direct nicotinic receptors activation.
In the present study, in spite of the decrease in pAkt1, surprisingly, an increase in pGSK3b was observed in both the hippocampus and cortex after KA administration. A similar Fig. 2 . Effects of KA and HX pre-treatment on Bcl2 in the hippocampus and cortex of C57BL/6 male mice. Photodensitometric quantification of WB experiments was used to evaluate changes in Bcl2 expression. Experiments (n = 4) were developed at least in duplicate on three to four animals and expressed as means AE S.E.M. The statistical analysis used was one-way ANOVA followed by Dunnett's test **p < 0.01 and ***p < 0.001 versus Control.
increase in pGSK3b has been previously reported in the hippocampus of mice treated by KA, as a compensatory attempt of self-protection by the cells [38] . Although pre-treatment with HX did not modify the KA effect on GSK3b, an increase in this protein was observed in 3xTg-AD mice after AChEI administration [12] .
Another important group of proteins is the caspase family, which seems to modulate critical regulatory networks controlling cell death. However, it is important to highlight that some authors have observed that calpain (but not caspase) activation is involved in neurotoxicity in the hippocampus after status epilepticus, suggesting that activation of caspases is not a crucial event in KA-induced apoptosis [39] . In this study, 48 hr after KA injection, no modification in the caspase-3/7 activity was observed in the cortex compared to control mice that it could be as a consequence of the significant increase in pGSK3b. It is known that GSK3b is involved in the activation of caspase to initiate the apoptosis process [40] . In the present conditions, pre-treatment by HX did not modify the caspase activity probably as KA did not affect the activity of this enzyme.
It is known that CDK5 activation requires the binding to the p35 or p39 peptide and is involved in neuroplasticity processes, while the pathological CDK5-p25 binding promotes apoptosis. In the present study, 2 days after KA administration, the p25/p35 ratio significantly increased in the hippocampus but not in the cortex. The administration HX totally prevented the effect of KA administration in the hippocampus, reinforcing the potential neuroprotective role of HX in the present experimental setting. However, no differences were detected in the cortex. Fig. 3 . Effects of KA and HX pre-treatment on pGSK3b and GSK3b in the hippocampus and cortex of C57BL/6 male mice. Photodensitometric quantification of WB experiments was used to evaluate changes in pGSK3b and GSK3b expression. Experiments (n = 4) were developed at least in duplicate on three to four animals and expressed as means AE S.E.M. The statistical analysis used was one-way ANOVA followed by Dunnett's test *p < 0.05, **p < 0.01, ***p < 0.001 versus control.
In regard to neuroplasticity, the synaptic marker synaptophysin was also analysed. A slight but not significant decrease in this protein after KA administration was observed. Similarly, Kriz et al. [41] also found no changes in synaptophysin expression after KA treatment. Interestingly, HX pre-treatment increased the synaptophysin content in both the hippocampus and cortex, which suggests a synaptic neuroprotection effect by the anticholinesterasic drug. An increase in synaptophysin expression in 3xTg-AD mice model was also reported after chronic administration of HX [13] .
In the present experimental approach, the effects of KA administration have shown a different pattern of response depending on both the factor/protein and the brain area analysed. Even though the hippocampus seems to be the most affected area by this neurotoxin, most of the parameters analysed in the present study have been similarly modified in both areas, even Bcl2 showed a greater decrease in cortex than in hippocampus. Similarly, the effects of pre-treatment with HX on KA injection did not show a regular pattern of responses in both cortex and hippocampus.
There is increasing evidence regarding the anti-inflammatory role of cholinergic system in both the peripheral and central nervous system through 7a-nAChR located in glial cells [42] . Chronic neuroinflammation is one of the most common features in neurodegenerative diseases, as it has been described in Parkinson's disease and AD, among others [43] . Microglia and astrocytes have a prominent protective role in acute inflammatory processes. However, they cause collateral neural cell damage in chronic inflammation. Also, during status epilepticus, an increase in GFAP (astrocytes) and Iba-1 (microglia) expression has been described.
In our study, the levels of GFAP increased significantly (88%) in the DG after KA administration, as compared with the control group that was totally prevented when mice were pre-treated with HX. The same results have been obtained using a microglia marker (antibody Iba-1). While microglia was activated after KA injection, pre-treatment with HX also prevented such an effect. This means that the anti-inflammatory effect of HX prevails even up to 3 days after the end of treatment. The presence and the role of 7a-nAChR in brain glial cells have been recently demonstrated. Indeed, activation of these receptors inhibits cytokines release in both astrocytes and microglia [44] , pointing to 7a-nAChR modulation as a novel therapeutic strategy in the treatment of neurodegenerative disorders, especially during chronic inflammation. We have previously demonstrated that HX has neuroprotective effects on differentiated PC12 cells [9] , being this effect mediated by nicotinic receptors. Consequently, the potent antiinflammatory effect of this anticholinesterasic compound Fig. 4 . Effects of KA and HX pre-treatment on p25/p35 ratio in the hippocampus and cortex of C57BL/6 male mice. Photodensitometric quantification of WB experiments was used to evaluate changes in the p25/p35 ratio. Experiments (n = 4) were developed at least in duplicate on three to four animals and expressed as means AE S.E.M. The statistical analysis used was one-way ANOVA followed by Dunnett's test *p < 0.05 versus control; ***p < 0.01 versus control; a p < 0.05 versus KA. observed in the present study could be due to both inhibition of AChE enzyme activity (increasing ACh level) and the direct agonistic action on nAChRs during chronic treatment. In addition, these data also corroborate the importance of cholinergic activity in brain inflammatory modulation.
Microglia, but not astrogliosis, is a mediator in the neurogenesis process [45] . However, microglia that express an inflammatory phenotype generally reduce cell proliferation, survival and function of new neurons whereas microglia displaying an alternative protective phenotype support adult neurogenesis [46] . In our experimental model, the marker of immature DCX neurons significantly decreased in the KA group suggesting an important decline in neurogenesis, while pre-treatment with HX was not able to protect mice against the KA effect on neurogenesis in spite of the prevention of Iba-1 increase. Nevertheless, neurogenesis is a complex process modulated by extrinsic and intrinsic factors that can be altered at several stages throughout the process [47] .
Finally, the alternative splicing patterns of AChE genes were also analysed, as it has been demonstrated that they are modified under stress insults. The RT-PCR analysis of the two AChE variants (-S, -R) showed that after KA administration the mRNA-S was not modified, while a significant increase in mRNA-R over the control group was observed. Although no data have been reported so far concerning the effects of KA on AChE variants, an increase in mRNA-R in the hippocampus of epileptic rats was observed by Zimmerman et al. who, as in our experimental conditions, did not detect any modification on the mRNA-S variant. The increase in the mRNA-R variant has been interpreted as a protection reaction of cells against KA injury [19] . Nevertheless, pre-treatment with the AChEI HX did not significantly modify the response induced by KA on the mRNA variant-R. Nonetheless, a positive correlation between up-regulation of AChE-R and positive response to AChEIs has been seen in Alzheimer patients, which suggests that the up-regulation of the highly secretory AChE-R variant may prevent a prolonged hyperexcitation of vulnerable neurons [20] . It is possible that the effects of HX on the mRNA-R variant were masked by the increase of the same AChE variant induced by KA administration in the present experimental conditions. In summary, in the present study, we have demonstrated that HX, a potent AChE inhibitor endowed with agonistic muscarinic and nicotinic AChRs activity, and an in vivo cognitiveenhancing effect, also displays neuroprotective activity against the neuronal injury caused by acute administration of KA. In this regard, pre-treatment with HX decreased the p25/p35 ratio and significantly increased the protein levels of synaptophysin, suggesting an improvement on neuroplasticity. Furthermore, we wish to highlight the importance of the anti-inflammatory effect (GFAP, Iba-1) observed after HX pre-treatment, as microglia seems to be a crucial point for the brain's immune system. This anti-inflammatory effect could be mediated indirectly by increasing the ACh levels in the synapsis upon AChE inhibition, or by a direct activation of nAChRs [7, 9] . Overall, these results support the relevance and therapeutic potential of AChEIs for the treatment of various diseases related to both cognitive deficits and chronic inflammatory processes [11] .
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